false 0001740279 0001740279 2024-09-06 2024-09-06

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 6, 2024

 

 

IN8bio, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-39692   82-5462585

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

350 5th Avenue, Suite 5330

New York, New York

   10118
(Address of Principal Executive Offices)   (Zip Code)

646 600-6438

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share   INAB   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02

Costs Associated with Exit or Disposal Activities.

On September 8, 2024, IN8bio, Inc. (the “Company”) and Trishna Goswami, M.D., the Company’s Chief Medical Officer, reached the mutual decision to have Dr. Goswami step down as Chief Medical Officer, effective September 6, 2024. The Company and Dr. Goswami entered into a separation agreement (the “Agreement”), pursuant to which Dr. Goswami will receive a cash severance benefit equal to the sum of two months of her annual base salary. Dr. Goswami also agreed to a general release of claims and to other customary non-disparagement, confidentiality and cooperation covenants.

The foregoing summary of the Agreement is not complete and is qualified in its entirety by the terms and conditions of the Agreement, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    IN8bio, Inc.
Dated: September 11, 2024     By:  

/s/ Patrick McCall

      Patrick McCall
     

Chief Financial Officer and Secretary

(Principal Financial and Accounting Officer)

v3.24.2.u1
Document and Entity Information
Sep. 06, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001740279
Document Type 8-K
Document Period End Date Sep. 06, 2024
Entity Registrant Name IN8bio, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39692
Entity Tax Identification Number 82-5462585
Entity Address, Address Line One 350 5th Avenue
Entity Address, Address Line Two Suite 5330
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10118
City Area Code 646
Local Phone Number 600-6438
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value per share
Trading Symbol INAB
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
IN8bio (NASDAQ:INAB)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024 Click aqui para mais gráficos IN8bio.
IN8bio (NASDAQ:INAB)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024 Click aqui para mais gráficos IN8bio.